Breast cancers can be identified by specific molecular subtypes based on gene expression within the cancer cells. The most common genes investigated for molecular subtyping of breast cancer are the estrogen receptor (ER) and progesterone receptor (PR), which are together classified as hormone receptor (HR), and human epidermal growth factor receptor (HER2), a protein that helps breast cancers grow. There are four major subtypes HR+/Her2- , HR-/HER2- (also known as triple negative breast cancer), HR+/HER2+, and HR-/HER2+.
Human solid tumors, like breast cancers, represent a heterogeneous group of diseases that is best demonstrated through many differences in clinical outcomes within homogenously treated patie...
Changes in transcriptional regulation are thought to be one of the key drivers of carcinogenesis. Although next-generation sequencer revolutionized transcriptome analysis, there are limitati...
Speaker TBD 10:30–10:50 am PDT Exploring the immune tumor microenvironment of hepatocellular carcinoma with Imaging Mass Cytometry™ 10:50 am–11:10 am PDT Presented By: Won...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
Tumors are often categorized into standard molecular subtypes. However, largescale studies have demonstrated that patient heterogeneity in the regulatory make-up of tumors remain. At the tran...
Acral lentiginous melanoma (ALM) is a rare sun-shielded melanoma subtype associated with worse survival than cutaneous melanoma (CM), a more common form of skin cancer linked to exposure to u...
DATE: January 27, 2017TIME: 4:00am PT, 7:00am ET, 1:00pm CETThe study of the tumor ecosystem and its cell-to-cell communications is essential to enable an understanding of tumor biology...
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Cancer metastases develop when tumor cells known as circulating tumor cells (CTCs) are shed from a tumor, circulate through the blood stream and colonize a distant tissue. The number of CTCs...
The eukaryotic translation initiation factor eIF4E is a potent oncogene estimated to be elevated in about 30% of human cancers including cancers of the breast, prostate, lung, colon as well a...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical...
In this presentation I describe some of the approaches we are taking to identify the genetic architecture of common complex cancers with a particular focus on the etiology of lung cancer. Can...
The eukaryotic translation initiation factor eIF4E is a potent oncogene estimated to be elevated in about 30% of human cancers including cancers of the breast, prostate, lung, colon as well ...
Human solid tumors, like breast cancers, represent a heterogeneous group of diseases that is best demonstrated through many differences in clinical outcomes within homogenously treated patie...
Changes in transcriptional regulation are thought to be one of the key drivers of carcinogenesis. Although next-generation sequencer revolutionized transcriptome analysis, there are limitati...
Speaker TBD 10:30–10:50 am PDT Exploring the immune tumor microenvironment of hepatocellular carcinoma with Imaging Mass Cytometry™ 10:50 am–11:10 am PDT Presented By: Won...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
Tumors are often categorized into standard molecular subtypes. However, largescale studies have demonstrated that patient heterogeneity in the regulatory make-up of tumors remain. At the tran...
Acral lentiginous melanoma (ALM) is a rare sun-shielded melanoma subtype associated with worse survival than cutaneous melanoma (CM), a more common form of skin cancer linked to exposure to u...
DATE: January 27, 2017TIME: 4:00am PT, 7:00am ET, 1:00pm CETThe study of the tumor ecosystem and its cell-to-cell communications is essential to enable an understanding of tumor biology...
DATE: November 16, 2016
TIME: 8:00am PT, 11:00am ET
Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer death among wo...
Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented mas...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Cancer metastases develop when tumor cells known as circulating tumor cells (CTCs) are shed from a tumor, circulate through the blood stream and colonize a distant tissue. The number of CTCs...
The eukaryotic translation initiation factor eIF4E is a potent oncogene estimated to be elevated in about 30% of human cancers including cancers of the breast, prostate, lung, colon as well a...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical...
In this presentation I describe some of the approaches we are taking to identify the genetic architecture of common complex cancers with a particular focus on the etiology of lung cancer. Can...
The eukaryotic translation initiation factor eIF4E is a potent oncogene estimated to be elevated in about 30% of human cancers including cancers of the breast, prostate, lung, colon as well ...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
